Double maintains 3 strategies that include CSTL - Castle Biosciences, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SO | <0.01% | $100.71B | +28.71% | 3.14% |
WMT | -0.01% | $712.14B | +50.15% | 0.97% |
CI | -0.02% | $89.74B | -8.84% | 1.73% |
TEF | -0.06% | $26.52B | +7.31% | 6.69% |
QNTM | -0.07% | $15.34M | -81.65% | 0.00% |
PRPO | 0.10% | $8.50M | -12.81% | 0.00% |
OXBR | -0.10% | $14.38M | +70.98% | 0.00% |
RTO | 0.10% | $11.56B | -23.77% | 2.53% |
SCKT | -0.11% | $8.83M | +7.77% | 0.00% |
HUM | -0.13% | $31.95B | -13.01% | 1.34% |
EXC | 0.19% | $46.36B | +22.19% | 3.35% |
XOS | 0.21% | $24.25M | -64.64% | 0.00% |
HLF | -0.22% | $891.55M | +5.51% | 0.00% |
NEXA | -0.22% | $814.50M | -15.41% | 0.00% |
ZBH | 0.23% | $22.37B | -12.53% | 0.86% |
HIHO | 0.25% | $8.01M | -14.15% | 6.59% |
ARIS | -0.27% | $1.01B | +127.58% | 1.42% |
RLMD | 0.30% | $9.08M | -94.46% | 0.00% |
JMIA | 0.31% | $266.97M | -57.17% | 0.00% |
OCFT | 0.31% | $248.36M | +209.63% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ITCI | -19.63% | $14.05B | +97.80% | 0.00% |
CBOE | -16.13% | $23.56B | +23.21% | 1.08% |
CHD | -15.26% | $26.94B | +4.62% | 1.04% |
PULM | -13.50% | $22.41M | +258.77% | 0.00% |
KMB | -13.27% | $47.44B | +12.01% | 3.44% |
KR | -12.25% | $49.31B | +17.85% | 1.83% |
PEP | -12.10% | $205.27B | -12.70% | 3.61% |
ODP | -11.50% | $417.16M | -73.13% | 0.00% |
DG | -11.39% | $19.27B | -43.44% | 2.68% |
ORGO | -11.27% | $542.82M | +63.98% | 0.00% |
PG | -10.51% | $399.94B | +6.22% | 2.36% |
MRK | -10.20% | $220.07B | -33.16% | 3.63% |
CPB | -9.94% | $11.90B | -10.18% | 3.75% |
VZ | -9.83% | $191.04B | +6.68% | 5.93% |
T | -9.56% | $204.43B | +62.56% | 3.91% |
GIS | -9.31% | $32.70B | -15.36% | 3.98% |
ENFN | -8.93% | $1.05B | +20.76% | 0.00% |
MO | -8.33% | $99.39B | +36.94% | 6.89% |
TSN | -8.10% | $22.04B | +9.57% | 3.13% |
CAG | -8.08% | $12.70B | -9.98% | 5.26% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 42.82% | $48.63M | 0.5% |
ARKG | 41.52% | $963.54M | 0.75% |
CPRJ | 41.03% | $48.36M | 0.69% |
SFYX | 40.00% | $24.47M | 0.06% |
SCHA | 39.23% | $15.90B | 0.04% |
NUSC | 39.09% | $1.10B | 0.31% |
VTWO | 38.97% | $10.85B | 0.07% |
KJUL | 38.94% | $155.04M | 0.79% |
IWM | 38.93% | $63.34B | 0.19% |
IWO | 38.67% | $10.75B | 0.24% |
IWC | 38.62% | $799.66M | 0.6% |
KJAN | 38.61% | $317.19M | 0.79% |
VXF | 38.55% | $20.01B | 0.05% |
ISCG | 38.46% | $652.91M | 0.06% |
FNY | 38.40% | $374.15M | 0.7% |
ESML | 38.37% | $1.75B | 0.17% |
GSSC | 38.37% | $513.14M | 0.2% |
SMLF | 38.11% | $1.74B | 0.15% |
PRFZ | 38.02% | $2.34B | 0.39% |
VBK | 37.86% | $17.43B | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -27.85% | $195.31M | 0.85% |
BTAL | -26.67% | $414.68M | 1.43% |
TAIL | -24.74% | $86.59M | 0.59% |
XBIL | -13.77% | $708.50M | 0.15% |
XHLF | -12.74% | $1.06B | 0.03% |
SGOV | -11.97% | $39.39B | 0.09% |
USDU | -11.64% | $207.14M | 0.5% |
BUXX | -11.52% | $231.45M | 0.25% |
CORN | -10.96% | $51.42M | 0.2% |
SOYB | -10.89% | $25.60M | 0.22% |
XONE | -10.76% | $633.49M | 0.03% |
TPMN | -10.27% | $33.32M | 0.65% |
IBTP | -9.52% | $109.02M | 0.07% |
UUP | -9.28% | $325.55M | 0.77% |
WEAT | -8.62% | $115.01M | 0.28% |
CCOR | -8.16% | $64.32M | 1.18% |
IBMS | -7.83% | $45.63M | 0.18% |
KMLM | -7.81% | $221.29M | 0.9% |
ULST | -7.24% | $587.14M | 0.2% |
USTB | -6.78% | $1.14B | 0.35% |
Current Value
$20.001 Year Return
Current Value
$20.001 Year Return
Yahoo
It is hard to get excited after looking at Castle Biosciences' (NASDAQ:CSTL) recent performance, when its stock has...
Yahoo
Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melanoma (CM) to help guide adjuvant therapy, and the role of the test in prompting use of imaging surveillance in early-stage patients at high risk of metastasis to the central nervous system (CNS) FRIENDSWOOD, Texas, April 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovat
Yahoo
New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk by National Comprehensive Cancer Network (NCCN) guidelines to support improved, risk-aligned treatment pathway decisions Castle will also present new data showing DecisionDx®-Melanoma as a significant predict
Yahoo
FRIENDSWOOD, Texas, March 07, 2025--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting.
Yahoo
Castle Biosciences, Inc.'s ( NASDAQ:CSTL ) earnings announcement last week was disappointing for investors, despite the...
Yahoo
Castle Biosciences, Inc. ( NASDAQ:CSTL ), might not be a large cap stock, but it saw significant share price movement...
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
JBND | 0.05% | $1.73B | 0.25% |
TFLO | 0.06% | $6.78B | 0.15% |
VCRB | -0.06% | $2.50B | 0.1% |
USCI | 0.08% | $237.61M | 1.07% |
DBA | 0.08% | $818.93M | 0.93% |
OWNS | 0.09% | $133.61M | 0.3% |
CLOI | 0.11% | $1.02B | 0.4% |
DBB | 0.13% | $123.76M | 0.77% |
DBC | -0.15% | $1.36B | 0.87% |
FTSD | 0.16% | $220.41M | 0.25% |
JPLD | 0.18% | $1.16B | 0.24% |
PDBC | 0.21% | $4.88B | 0.59% |
HYMB | -0.21% | $2.75B | 0.35% |
TFI | -0.23% | $3.28B | 0.23% |
BSV | -0.23% | $34.55B | 0.03% |
TDTF | -0.25% | $809.57M | 0.18% |
YEAR | -0.29% | $1.28B | 0.25% |
FLIA | 0.31% | $625.58M | 0.25% |
FTGC | 0.33% | $2.51B | 1.02% |
BSSX | -0.35% | $75.70M | 0.18% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NEO | 40.48% | $1.20B | -36.87% | 0.00% |
PUBM | 39.92% | $450.82M | -60.67% | 0.00% |
VCYT | 38.65% | $2.30B | +44.12% | 0.00% |
ACA | 38.01% | $3.81B | -5.98% | 0.26% |
ADSK | 37.47% | $56.36B | +6.39% | 0.00% |
PGRE | 37.41% | $941.90M | -2.70% | 0.82% |
RDNT | 36.80% | $3.75B | +5.46% | 0.00% |
BEAM | 36.72% | $1.76B | -42.28% | 0.00% |
NOVT | 36.66% | $4.58B | -24.09% | 0.00% |
MAC | 35.48% | $4.31B | +5.18% | 4.05% |
MYGN | 35.11% | $807.17M | -55.80% | 0.00% |
VNO | 34.39% | $7.20B | +38.74% | 1.98% |
RRX | 33.80% | $7.61B | -34.21% | 1.24% |
SLG | 33.66% | $4.38B | +12.78% | 5.31% |
KN | 33.57% | $1.33B | -5.90% | 0.00% |
GH | 33.52% | $5.24B | +104.28% | 0.00% |
CUZ | 33.41% | $4.94B | +28.72% | 4.39% |
FLGT | 33.25% | $534.29M | -18.62% | 0.00% |
BRZE | 33.13% | $3.76B | -15.89% | 0.00% |
PRAX | 33.10% | $723.26M | -35.45% | 0.00% |